Huang et al., 2010 - Google Patents
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptinHuang et al., 2010
View PDF- Document ID
- 13710280464023784488
- Author
- Huang X
- Gao L
- Wang S
- McManaman J
- Thor A
- Yang X
- Esteva F
- Liu B
- Publication year
- Publication venue
- Cancer research
External Links
Snippet
Primary and acquired resistance to the breast cancer drug trastuzumab (Herceptin) is a significant clinical problem. Here, we report enhanced activation of downstream signaling pathways emanating from the growth factor receptors erbB2, erbB3, and insulin-like growth …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin | |
| Necela et al. | Folate receptor-α (FOLR1) expression and function in triple negative tumors | |
| DiGiovanna et al. | Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients | |
| Press et al. | HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer | |
| Mai et al. | PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma | |
| Mitra et al. | An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance | |
| Yang et al. | Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens | |
| Begnami et al. | Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome | |
| Miller et al. | Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer | |
| Nahta et al. | Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | |
| Garrett et al. | Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function | |
| Ghosh et al. | Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers | |
| Iqbal et al. | Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications | |
| Scaltriti et al. | Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer | |
| Zhuang et al. | Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy | |
| Zhang et al. | Antitumor activity of epidermal growth factor receptor–related protein is mediated by inactivation of ErbB receptors and nuclear factor-κB in pancreatic cancer | |
| Stern et al. | PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance | |
| Xu et al. | S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling | |
| Liu et al. | Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer | |
| Iyer et al. | ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer | |
| Mohan et al. | Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells | |
| Arienti et al. | Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer | |
| Wilken et al. | Primary trastuzumab resistance: new tricks for an old drug | |
| Deguchi et al. | PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma | |
| Meng et al. | Annexin A3 gene silencing promotes myocardial cell repair through activation of the PI3K/Akt signaling pathway in rats with acute myocardial infarction |